PUBLIC COMPANY
save$MPLTMapLight Therapeutics, Inc.
$MPLT11.24-4.30%Redwood City, CA, USupdated 9h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- phase2A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- phase2A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- phase2ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
- phase2A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
- phase2ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 16, 26SELLKroeger Christopher A.· Chief Executive Officer−$208K↗
- Apr 16, 26SELLKroeger Christopher A.· Chief Executive Officer−$67K↗
- Apr 16, 26SELLLillie James Woodruff· Chief Scientific Officer−$58K↗
- Apr 16, 26SELLFoff Erin Pennock· Chief Medical Officer−$24K↗
- Apr 16, 26SELLLillie James Woodruff· Chief Scientific Officer−$19K↗
- Apr 16, 26SELLFoff Erin Pennock· Chief Medical Officer−$8K↗
- Apr 16, 26SELLHanson Kristopher· General Counsel−$6K↗
- Apr 16, 26SELLSetia Vishwas· Chief Financial Officer−$2K↗
- Apr 16, 26SELLHanson Kristopher· General Counsel−$2K↗
- Apr 16, 26SELLSetia Vishwas· Chief Financial Officer−$783↗
- Apr 15, 26SELLKroeger Christopher A.· Chief Executive Officer−$246K↗
- Apr 15, 26SELLMalenka Robert C.· −$231K↗
- Apr 15, 26SELLGILLIS JONATHAN· CAAO and PAO−$96K↗
- Apr 15, 26SELLKreitzer Anatol· Chief Discovery Officer−$88K↗
- Apr 15, 26SELLSetia Vishwas· Chief Financial Officer−$75K↗
- Apr 15, 26SELLFoff Erin Pennock· Chief Medical Officer−$55K↗
- Apr 15, 26SELLLillie James Woodruff· Chief Scientific Officer−$46K↗
- Apr 15, 26SELLHanson Kristopher· General Counsel−$41K↗
- Feb 24, 26SELLMalenka Robert C.· −$13K↗
- Feb 23, 26SELLMalenka Robert C.· −$198K↗
🐶 Hiring Signal
News
- As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the doorDespite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…biospace · 8d ago
- MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 winMapLight Therapeutics’ stock {$MPLT} plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage trial, despite the study’s ove…endpoints · 21d ago
- MapLight’s schizophrenia drug dampens once-daily hopes despite Phase 2 winMapLight Therapeutics’ stock {$MPLT} plummeted more than 60% on Monday after a once-daily regimen of its schizophrenia drug missed the primary endpoint in a mid-stage trial, despite the study’s ove…endpoints · 21d ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that